Sunday, May 11

Elan shares soar on news of possible Tysabri side-effect treatment

SHARES IN drug company Elan bounced more than 10 per cent yesterday after news emerged of a possible treatment for a potentially fatal side effect of its multiple sclerosis therapy, Tysabri.

Biogen Idec, Elan’s partner in the development and sale of Tysabri, is testing the efficacy of a malaria pill developed during the Vietnam war in treating progressive multifocal leukoencephalopathy (PML), the brain infection that has been tied to use of Tysabri, according to Al Sandrock, Biogen’s head of neurology research....full story in